Cannabis Bioscience Delays Quarterly Report as Annual Audit Remains Incomplete
Bitget2026/10/16 21:01- Cannabis Bioscience International Holdings delayed its Form 10-Q for the quarter ended August 31, 2026, because financial information could not be completed.
- The fiscal year ended May 31, 2026, audit remains unfinished, preventing completion of quarterly statements; the annual report also remains unfiled.
- Filing within the five-day extension period is not assured.
- Quarterly revenue is expected at approximately $1,000 versus $24,200 a year earlier, reflecting the clinical-trial business’s July 31, 2026, termination.
- Net loss is projected at approximately $172,000 versus $82,645 a year earlier, reflecting higher compensation costs, increased interest expense and absent derivative-related gains.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pyth October Report: ARR Jumps 18.9% as Data Expansion Accelerates
Elon Musk: SpaceX (SPCX.US) Q4 revenue is expected to increase by approximately 70% quarter-on-quarter, with government contract income share falling below 10%
Elon Musk stated on Friday that SpaceX (SPCX.US) will continue to reduce its dependence on U.S. government procurement contracts.
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Crypto prices
More
